Eamon Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 7.24 M
- Company Age 39 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.20 Cr
- Revenue Growth 20.39%
- Profit Growth 31.87%
- Ebitda 11.48%
- Net Worth 15.30%
- Total Assets 29.08%
About Eamon Drugs
Eamon Drugs Private Limited (EDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 04 September 1985 and has a history of 39 years and four months. Its registered office is in Indore, Madhya Pradesh, India.
The Corporate was formerly known as Shyra Chemicals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 7.24 M.
The company currently has active open charges totaling ₹2.20 Cr.
Mahendra Mandloi, Udit Sodani, and Rishabh Mandloi serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24114MP1985PTC003021
-
Company No.
003021
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Sep 1985
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Eamon Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahendra Mandloi
|
Director | 25-Jan-2018 | Current |
|
Udit Sodani
|
Director | 25-Jan-2018 | Current |
|
Rishabh Mandloi
|
Director | 14-Jul-2020 | Current |
Financial Performance of Eamon Drugs.
Eamon Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 20.39% increase. The company also saw a substantial improvement in profitability, with a 31.87% increase in profit. The company's net worth Soared by an impressive increase of 15.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eamon Drugs?
In 2023, Eamon Drugs had a promoter holding of 76.00% and a public holding of 24.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Ishika Consultancy Services Pvt LtdUdit Sodani is a mutual person
Charges (Loans)
₹2.20 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 2.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Oct 2024 | Others | ₹2.00 M | Open |
| 07 Mar 2023 | Others | ₹2.00 Cr | Open |
How Many Employees Work at Eamon Drugs?
Eamon Drugs has a workforce of 18 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eamon Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eamon Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
